Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015 (2015), Article ID 173218, 8 pages
Research Article

Polymorphism in LEP and LEPR May Modify Leptin Levels and Represent Risk Factors for Thyroid Cancer

1Laboratory of Cancer Molecular Genetics (Gemoca), Faculty of Medical Sciences, University of Campinas (FCM-Unicamp), Rua Tessalia Vieira de Camargo 126, 13083-970 Campinas, SP, Brazil
2Laboratory of Investigation on Metabolism and Diabetes (LIMED), Faculty of Medical Sciences, University of Campinas (FCM-Unicamp), Rua Carlos Chagas 420, 13083-878 Campinas, SP, Brazil
3Service of Nuclear Medicine, University of Campinas, Rua Vital Brasil 251, 13083-888 Campinas, SP, Brazil
4Service of Endocrinology, University of Campinas, Rua Vital Brasil 251, 13083-888 Campinas, SP, Brazil
5Department of Head and Neck Surgery, Barretos Cancer Hospital, Rua Antenor Duarte Vilela 1331, 14784-400 Barretos, SP, Brazil

Received 6 January 2015; Accepted 13 February 2015

Academic Editor: Giuseppe Damante

Copyright © 2015 Marjory Alana Marcello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To understand the role of polymorphisms in the LEP (rs7799039 and rs2167270) and LEPR (rs1137101 and rs1137100) genes in DTC susceptibility and their effect on leptin levels. Methods. We studied 153 patients with DTC and 234 controls through TaqMan SNP Genotyping and ELISA, comparing these data to the clinicopathological data of patients with DTC. Results. Patients with AA genotype of rs7799039 had higher levels of serum leptin ( ng/mL) than those with AG genotype ( ng/mL; ). Individuals with AG genotype of rs2167270 also produced higher serum leptin levels ( ng/mL) than the subjects with GG genotype ( ng/mL; ). A multivariate logistic regression adjusted for gender, age, and BMI showed that the AG genotype of rs7799039 was an independent risk for DTC (OR, 11.689; ; 95% CI, 1.516–90.119). Similarly, AG and GG genotypes of rs1137101 increased the susceptibility to DTC (OR, 3.747; ; 95% CI, 1.161–12.092 and OR, 5.437; ; 95% CI, 1.426–20.729). Conclusions. We demonstrated that rs7799039 and rs2167270 polymorphisms modify the serum leptin concentrations in patients with DTC. Furthermore, polymorphisms rs7799039 and rs1137101 increase the risk of DTC development, although they do not correlate with tumor aggressiveness.